Diacerein

Drug Profile

Diacerein

Alternative Names: Art 50; Artrodar; Artrolyt; Cartivix; Diacerhein; Diacetylrhein; Fisiodar; Galaxdar; KW 4800; Matrix; Rhein diacetate; SF 277; Verboril

Latest Information Update: 25 Feb 2016

Price : $50

At a glance

  • Originator Istituto Gentili; Proter
  • Developer Abiogen Pharma; Ecupharma; Faran; Istituto Gentili; Kyowa Hakko; Lacer; Myungmoon Pharm; Neo-Farmaceutica; Proter; TRB Pharma; Wockhardt
  • Class Anthraquinones; Anti-inflammatories; Antihyperglycaemics; Antirheumatics; Small molecules
  • Mechanism of Action Interleukin 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Osteoarthritis

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 10 Feb 2016 TRB Chemedica International plans the phase III/IV DISSCO trial for Osteoarthritis (In adults, In the elderly) in Canada, Spain, Austria and Czech Republic (PO) (NCT02688400)
  • 07 Mar 2014 Pharmacovigilance Risk Assessment Committee recommends restrictions of diacerein availability in Osteoarthritis to manage risk of adverse events in the European Union
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top